Drug Channels

DECEMBER 19, 2021

Ring in 2022 with these noisemakers from the Drug Channels party bag: Hospitals earn incredible markups on CAR-T therapies Utilization management booms Health plans often ignore clinical guidelines Benefit designs flummox physicians Plus: an awesomely concise summary of U.S. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc.

Hospitals 98

Hospitals Therapies Drugs 98

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Drug Channels

JANUARY 13, 2023

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. He describes CoverMyMeds’ provider alerts solution, which is designed to minimize medication errors. Read on for Clay’s insights.

Therapies 98

Therapies Production Drugs 98

Drug Target Review

JUNE 2, 2025

Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. The addition of Drug Product assets for cytotoxic substances completes the fully integrated offering.

Small Molecule 52

Small Molecule Engineering Therapies Drugs 52

Drug Channels

OCTOBER 17, 2024

They argue that a technology-enabled infrastructure, combined with clinical and reimbursement support specialists, can improve patients' access to new therapies, shorten the time to therapy, and enable better overall clinical outcomes. Click here to learn more about EVERSANA’s Direct-to-Patient care model. All rights reserved.

Therapies 96

Therapies Drugs 96

Drug Channels

APRIL 14, 2023

Edward discusses how a technology-first approach automates manual processes for therapy initiation. He argues that such an approach can increase patient adherence, speed access to therapy, and improve the healthcare providers’ workflow. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Therapies Drugs 98

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Channels

SEPTEMBER 8, 2023

Nasir discusses how hubs help patients initiate and adhere to drug therapies. Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. d/b/a Drug Channels Institute.

Pharmaceuticals 97

Pharmaceuticals Therapies Production Drugs 97

Drug Channels

APRIL 15, 2022

Megan discusses the access and affordability challenges faced by specialty therapy patients. She describes how CoverMyMeds’ centralized technology solutions—paired with experts familiar with each therapy—help patients navigate these challenges. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Therapies Drugs 97

Drug Channels

APRIL 28, 2023

She describes how human care plus an innovative, technology-driven patient support solution can help patients start therapy and get on the road to recovery. To learn more about CoverMyMeds’ specialty therapy solutions , visit Booth 1519 at Asembia's Specialty Pharmacy Summit in Las Vegas, April 30-May 4, 2023.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Therapies Drugs 98

Drug Channels

MARCH 3, 2023

Jan discusses digital hubs and the benefits they offer both patients on specialty therapies and their health care providers. To learn more, download AssistRx's free 61-page eBook: Specialty Drug Patient Support Programs: 2022 Progress Report. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Therapies 97

Therapies Drugs 97

Drug Channels

FEBRUARY 11, 2022

He describes patient-centric, data-driven solutions to help patients access, afford, and adhere to their therapies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for John’s insights.

Therapies 98

Therapies Drugs 98

Drug Channels

MARCH 4, 2022

Miranda discusses how integrated technology solutions can be used at critical moments in the patient’s journey to increase access, affordability, and adherence to therapies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read on for Miranda’s insights.

Therapies 98

Therapies Drugs 98

Drug Channels

MARCH 28, 2024

Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Today’s guest post comes from Bill Dupere, SVP of Product Development & Partnerships at Mercalis.

Marketing 98

Marketing Science Therapies Production 98

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 97

Biosimilars Pharmacy Therapies Production 97

Drug Channels

MARCH 22, 2024

Adam discusses how patients seeking to access specialty therapies can benefit from a digital intake approach. To learn about AssistRx’s digital intake solutions, download Digital Intake for Specialty Drug Programs: Q1 2024 Progress Report. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Pharmaceutical Companies 98

Pharmaceutical Companies Therapies Pharmaceuticals Drugs 98

Drug Channels

DECEMBER 8, 2023

Kelly discusses the obstacles that patients face when attempting to access, afford, and adhere to specialty therapies. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Kelly’s insights.

Therapies 98

Therapies Production Drugs 98

Drug Channels

JUNE 17, 2022

Shawn discusses how technology can be combined with human intervention to better help patients access, afford, and adhere to their therapies. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Therapies 98

Therapies Drugs 98

Drug Channels

MARCH 11, 2022

Learn more about AssistRx’s specialty therapy initiation and patient support services at Asembia's Specialty Pharmacy Summit on May 2-5, 2022. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Therapies Marketing 97

Drug Channels

MARCH 10, 2023

Stacey discusses digital hubs and the affordability advantages they offer both patients on specialty therapies and their health care providers. Download AssistRx's free 61-page eBook here: Specialty Drug Patient Support Programs: 2022 Progress Report. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Therapies Marketing 98

Drug Channels

NOVEMBER 4, 2022

He suggests that lessons learned from the COVID-19 pandemic can inform both innovation in AMR therapies and our understanding of AMR. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Therapies 98

Therapies Marketing Drugs 98

Drug Channels

JULY 21, 2023

He explains how an electronic prior authorization solution can reduce delays and help patients start their therapies sooner—especially when patients and brands can play an active role in the process. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read on for Brent’s insights.

Therapies 98

Therapies Production Drugs 98

Drug Channels

NOVEMBER 17, 2023

Maria discusses the challenges patients and healthcare providers face accessing specialty therapies. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Maria’s insights.

Pharmacy 97

Pharmacy Therapies Drugs 97

Drug Channels

AUGUST 11, 2023

Today’s guest post comes from Rebecca Cotton, Executive Director of Strategy & Product Innovation at Cardinal Health ™ Sonexus ™ Access and Patient Support Rebecca discusses the essential features biopharmaceutical manufacturers should seek in a digital hub that will help patients get their therapies faster. d/b/a Drug Channels Institute.

Therapies 94

Therapies Production Drugs 94

Drug Channels

JANUARY 12, 2024

Maria, Krista, and Mike discuss the key reasons why patients abandon drug therapy. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. They then describe EVERSANA’s approach for helping manufacturers and healthcare providers improve adherence and health outcomes.

Therapies 98

Therapies Drugs 98

Drug Channels

AUGUST 4, 2023

Jonas describes the challenges patients face when accessing specialty therapies and explains how patient abandonment affects manufacturers over time. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Therapies 98

Therapies Production Drugs 98

Drug Channels

AUGUST 18, 2023

Divya discusses the challenges patients face in accessing specialty therapies prescribed by their healthcare providers. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Divya’s insights.

Treatment 98

Treatment Therapies Drugs 98

Drug Channels

AUGUST 5, 2022

She argues that manufacturers adopt an electronic health record-based solution to facilitate access to therapies, from the point of prescription through the point of dispensing at the pharmacy. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. d/b/a Drug Channels Institute.

Pharmacy 98

Pharmacy Therapies Marketing Drugs 98

Drug Channels

APRIL 8, 2022

To learn more about CoAssist and AssistRx specialty therapy initiation and patient support services, click here to schedule a meeting with AssistRx at the Asembia Specialty Pharmacy Summit on May 2-5, 2022. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read on for Michael’s insights.

Specialty Pharmacies 96

Specialty Pharmacies Pharmacy Production Therapies 96

Drug Channels

OCTOBER 1, 2021

David discusses how electronic prior authorization (ePA) and first-fill, buy-down programs can boost patient adherence to specialty therapies. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Therapies 95

Therapies Production Drugs 95

Drug Channels

FEBRUARY 2, 2024

She highlights how GoodRx’s integrated pharma copay cards help to improve medication access, therapy adherence, and overall health outcomes. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Read on for Divya’s insights. All rights reserved.

Therapies 98

Therapies Marketing Research Drugs 98

Drug Channels

JUNE 14, 2022

Last week, the authors of a new JAMA study claimed that “prices for new drugs are skyrocketing.” Most notably, the authors discount the fact that the most expensive new drugs treat ultra-rare conditions affecting extraordinarily small patient populations. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Links below.

Drugs 98

Drugs Disease Pharmaceuticals Treatment 98

Drug Channels

MAY 9, 2024

Today’s guest post comes from Hannah Baxter, Associate Partner at The Dedham Group; Jen Klarer, Partner, Head of Cell & Gene Therapy at The Dedham Group; and Carolyn Zele, Advisor, Solution Consulting at MMIT. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Therapies 98

Therapies Marketing Drugs 98

Drug Channels

OCTOBER 28, 2022

Brooks introduces us to CareMetx’s specialty therapy warranty, a specialty patient outcome-based contract model. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Therapies 52

Therapies Production Drugs 52

Drug Channels

SEPTEMBER 17, 2021

Vicki discusses the advantages of integrated technology solutions in enhancing specialty patients' access to therapy, affordability, and adherence. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc.

Therapies 90

Therapies Drugs 90

Drug Channels

APRIL 4, 2022

Drug Channels readers will save 10% off when they use code 22DRCH10 and register prior to April 29, 2022.*. Come together with experts from across the rare disease community, in-person or virtually, to unite in areas of unmet medical need and create life-transforming therapies and breakthroughs. Drug Channels, or any of its employees.

Disease 98

Disease Therapies FDA Trials 98

New Drug Approvals

MAY 17, 2025

4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7] gmol 1 References ^ “Register of Innovative Drugs” Health Canada. 3 November 2006. 4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7] 3 November 2006.

FDA Approval 62

FDA Approval FDA Treatment Clinical Trials 62